Søren Weis Dahl
Direttore/Membro del Consiglio presso PILA PHARMA AB
Posizioni attive di Søren Weis Dahl
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| PILA PHARMA AB | Direttore/Membro del Consiglio | 30/05/2023 | - |
Deck Therapeutics, Inc.
 Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deck Therapeutics, Inc. is an American acute omega-3 fatty acid therapeutics development company. Søren Weis Dahl has been the CEO of the company since 2020. | Direttore/Membro del Consiglio | 01/01/2014 | - |
| Amministratore Delegato | 01/01/2014 | - |
Storia della carriera di Søren Weis Dahl
Precedenti posizioni note di Søren Weis Dahl
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Prophylix AS
 Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Amministratore Delegato | 01/04/2015 | 01/01/2019 |
Formazione di Søren Weis Dahl
| Copenhagen Business School | Masters Business Admin |
| Technical University of Denmark | Graduate Degree |
Statistiche
Distribuzione geografica
| Danimarca | 3 |
| Norvegia | 2 |
| Svezia | 2 |
Posizioni
| Chief Executive Officer | 2 |
| Director/Board Member | 2 |
| Graduate Degree | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| PILA PHARMA AB | Health Technology |
| Aziende private | 2 |
|---|---|
Prophylix AS
Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Health Technology |
Deck Therapeutics, Inc.
Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deck Therapeutics, Inc. is an American acute omega-3 fatty acid therapeutics development company. Søren Weis Dahl has been the CEO of the company since 2020. | Health Technology |
- Borsa valori
- Insiders
- Søren Weis Dahl
- Esperienza
